Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Immunology (Baltimore, Md. : 1950)|August 26, 2020
Blockade of the G-CSF Receptor Is Protective in a Mouse Model of Renal Ischemia-Reperfusion InjuryJennifer L McRae, Ingela B Vikstrom, Anjan K Bongoni, et al.
Scientific Reports|November 9, 2021
A potent truncated form of human soluble CR1 is protective in a mouse model of renal ischemia-reperfusion injuryAnjan K Bongoni, Ingela B Vikstrom, Jennifer L McRae, et al.
Vaccine|August 30, 2008
Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infectionsAbigail Clements, Adam W Jenney, Jacinta L Farn, et al.
Xenotransplantation|April 16, 2003
Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promotersPeter J Cowan, Trixie A Shinkel, Nella Fisicaro, et al.
Frontiers in Immunology|March 9, 2018
Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild ReleaseRuth Pye, Amanda Patchett, Elspeth McLennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumorsEugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
The Journal of Biological Chemistry|March 21, 2007
Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptidesAbigail Clements, Dedreia Tull, Adam W Jenney, et al.
Vaccine|November 9, 2004
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasiaIan H Frazer, Michael Quinn, Jim L Nicklin, et al.
Scientific Reports|March 10, 2017
Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devilsCesar Tovar, Ruth J Pye, Alexandre Kreiss, et al.
Pageof 2